Patents by Inventor Boro Dropulic

Boro Dropulic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Methods for Treating Cancer with DuoCARs
    Publication number: 20220281946
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Application
    Filed: May 25, 2022
    Publication date: September 8, 2022
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SELF-DRIVING CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20220168344
    Abstract: Self-driving surface antigen-regulated promoter-therapeutic payload constructs containing antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the surface antigen-regulated promoter-therapeutic payload constructs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making self-driving surface antigen-regulated promoter-therapeutic payload constructs in T-cells are also disclosed.
    Type: Application
    Filed: March 6, 2020
    Publication date: June 2, 2022
    Inventors: Dina Schneider, Boro Dropulic, Brian Robert Webster
  • Compositions and Methods for Treating Cancer with DuoCARs
    Publication number: 20220169698
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Application
    Filed: December 2, 2021
    Publication date: June 2, 2022
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
    Patent number: 11242389
    Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: February 8, 2022
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
  • Compositions and methods for treating cancer with DuoCARs
    Patent number: 11208455
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: December 28, 2021
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Compositions and Methods for Treating Cancer with TSLPR-CD19 or TSLPR-CD22 Immunotherapy
    Publication number: 20210379110
    Abstract: Chimeric antigen receptors containing TSLPR-CD19 and TSLPR-CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 9, 2021
    Inventors: Dina Schneider, Boro Dropulic, Terry James Fry
  • COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-BCMA IMMUNOTHERAPY
    Publication number: 20210361709
    Abstract: Chimeric antigen receptors containing BCMA antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: June 2, 2021
    Publication date: November 25, 2021
    Inventors: Dina Schneider, Zhongyu Zhu, Boro Dropulic, Bang Khoa Vu, Leah Marie Alabanza
  • Compositions and Methods for Treating Cancer with Anti-CD38 Immunotherapy
    Publication number: 20210353675
    Abstract: Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: May 27, 2021
    Publication date: November 18, 2021
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with anti-CD38 immunotherapy
    Patent number: 11103533
    Abstract: Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: August 31, 2021
    Assignees: Lentigen Technology, Inc., The U.S.A., as represented by The Secretary, Department of Health and Human Services
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • COMPOSITIONS AND METHODS FOR TREATING HIV/AIDS WITH IMMUNOTHERAPY
    Publication number: 20210206839
    Abstract: Chimeric antigen receptors (CARs) containing HIV envelope antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing HIV-infection in a subject, and methods of making CAR T cells are also disclosed. Results of treating or preventing HIV-infection, and results of making CAR T cells are also disclosed.
    Type: Application
    Filed: December 15, 2020
    Publication date: July 8, 2021
    Inventors: Kim Anthony Gonda, Dina Schneider, Rimas Orentas, Boro Dropulic
  • Compositions and methods for treating cancer with anti-BCMA immunotherapy
    Patent number: 11052112
    Abstract: Chimeric antigen receptors containing BCMA antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: July 6, 2021
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Dina Schneider, Zhongyu Zhu, Boro Dropulic, Bang Khoa Vu, Leah Marie Alabanza
  • Compositions and methods for treating cancer with anti-CD38 immunotherapy
    Patent number: 11045497
    Abstract: Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: June 29, 2021
    Assignees: Lentigen Technology, Inc., The U.S.A., as represented by The Secretary, Department of Health and Human Services
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and Methods for Treating Cancer with Anti-CD19/CD22 Immunotherapy
    Publication number: 20210171632
    Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: October 16, 2020
    Publication date: June 10, 2021
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
  • Compositions and Methods for Treating Cancer with Anti-CD19/CD22 Immunotherapy
    Publication number: 20210171633
    Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: November 5, 2020
    Publication date: June 10, 2021
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
  • Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
    Publication number: 20210130479
    Abstract: Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 6, 2021
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating HIV/AIDS with immunotherapy
    Patent number: 10894819
    Abstract: Chimeric antigen receptors (CARs) containing HIV envelope antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing HIV-infection in a subject, and methods of making CAR T cells are also disclosed. Results of treating or preventing HIV-infection, and results of making CAR T cells are also disclosed.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: January 19, 2021
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Kim Anthony Gonda, Dina Schneider, Rimas Orentas, Boro Dropulic
  • Compositions and Methods for Treating Cancer with DuoCARs
    Publication number: 20200392200
    Abstract: Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Application
    Filed: June 22, 2020
    Publication date: December 17, 2020
    Inventors: Rimas J. Orentas, Dina Schneider, Waleed M. Haso, Stefan Miltenyi, Boro Dropulic
  • Compositions and methods for treating cancer with anti-CD123 immunotherapy
    Patent number: 10844128
    Abstract: Chimeric antigen receptors containing CD123 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: November 24, 2020
    Assignees: Lentigen Technology, Inc., The U.S.A., as represented by The Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy
    Patent number: 10822412
    Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: November 3, 2020
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
  • Method to Treat Cancer with Engineered T-Cells
    Publication number: 20200297769
    Abstract: Novel adoptive immunotherapy compositions comprising co-cultured lentiviral vector-transduced autologous antigen presentation cells and T cells are provided herein as well as are methods of use of same in a patient-specific combination immunotherapy that can be used to treat cancers and other diseases and conditions.
    Type: Application
    Filed: May 1, 2020
    Publication date: September 24, 2020
    Inventors: Boro Dropulic, Rimas J. Orentas, Dina Schneider, Winfried Krueger